Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.01.2021 | Case report

Azathioprine/tacrolimus/steroids

Hepatitis-C reactivation: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Yibirin M, et al. Safety of immune checkpoint inhibitors in cancer patients with chronic hepatitis C infection: A prospective observational study. Hepatology 72 (Suppl.): 571A-572A (plus poster) abstr. 933, No. 1, Nov 2020. Available from: URL: http://doi.org/10.1002/hep.31579 [abstract] Yibirin M, et al. Safety of immune checkpoint inhibitors in cancer patients with chronic hepatitis C infection: A prospective observational study. Hepatology 72 (Suppl.): 571A-572A (plus poster) abstr. 933, No. 1, Nov 2020. Available from: URL: http://​doi.​org/​10.​1002/​hep.​31579 [abstract]
Metadaten
Titel
Azathioprine/tacrolimus/steroids
Hepatitis-C reactivation: case report
Publikationsdatum
01.01.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-87972-9

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Oseltamivir

Case report

Thiamazole

Case report

Quetiapine